Crestwood Advisors Group LLC Has $35.65 Million Stake in Zoetis Inc. (NYSE:ZTS)

Crestwood Advisors Group LLC lowered its stake in Zoetis Inc. (NYSE:ZTS) by 1.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 218,775 shares of the company’s stock after selling 3,563 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Zoetis were worth $35,645,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ZTS. IFP Advisors Inc grew its holdings in Zoetis by 13.0% in the fourth quarter. IFP Advisors Inc now owns 10,033 shares of the company’s stock worth $1,635,000 after purchasing an additional 1,158 shares during the period. Waverton Investment Management Ltd grew its stake in shares of Zoetis by 7.2% in the 4th quarter. Waverton Investment Management Ltd now owns 335,536 shares of the company’s stock valued at $54,707,000 after buying an additional 22,637 shares during the period. New World Advisors LLC grew its stake in shares of Zoetis by 22.9% in the 4th quarter. New World Advisors LLC now owns 3,384 shares of the company’s stock valued at $551,000 after buying an additional 631 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Zoetis in the 4th quarter valued at about $3,530,000. Finally, Union Bancaire Privee UBP SA acquired a new position in Zoetis during the 4th quarter worth approximately $898,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

ZTS has been the subject of a number of research reports. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Piper Sandler reduced their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $215.40.

Zoetis Trading Up 1.9 %

Shares of ZTS stock opened at $160.39 on Monday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market capitalization of $71.82 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a 50-day simple moving average of $166.51 and a two-hundred day simple moving average of $177.94.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.